ArticleBlood2021

A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study).

Erica Brivio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.